×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SCYX – scynexis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SCYX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/8
08:00 am
scyx
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Medium
Report
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
3/22
02:04 am
scyx
SCYNEXIS, Inc. (NASDAQ: SCYX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Neutral
Report
SCYNEXIS, Inc. (NASDAQ: SCYX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/13
11:02 pm
scyx
SCYNEXIS, Inc. (NASDAQ: SCYX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
SCYNEXIS, Inc. (NASDAQ: SCYX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/12
05:08 pm
scyx
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
2/20
12:40 pm
scyx
NanoNewron and its Research to Advance the Treatment of Alzheimer's Disease are Featured by Rutgers University Newsletters and on Rutgers Today [Yahoo! Finance]
Low
Report
NanoNewron and its Research to Advance the Treatment of Alzheimer's Disease are Featured by Rutgers University Newsletters and on Rutgers Today [Yahoo! Finance]
2/5
06:23 am
scyx
Candidiasis Global Clinical Trials Review 2024: Top Countries, Trial Status, Trial Phase, Sponsor Type and End Point Status [Yahoo! Finance]
Medium
Report
Candidiasis Global Clinical Trials Review 2024: Top Countries, Trial Status, Trial Phase, Sponsor Type and End Point Status [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
08:02 am
scyx
Form 4 SCYNEXIS INC For: Apr 09 Filed by: Angulo Gonzalez David
Low
Report
Form 4 SCYNEXIS INC For: Apr 09 Filed by: Angulo Gonzalez David
3/20
07:39 pm
scyx
Form 4 SCYNEXIS INC For: Mar 19 Filed by: Angulo Gonzalez David
Neutral
Report
Form 4 SCYNEXIS INC For: Mar 19 Filed by: Angulo Gonzalez David
3/12
04:56 pm
scyx
Form 10-K SCYNEXIS INC For: Dec 31
Medium
Report
Form 10-K SCYNEXIS INC For: Dec 31
2/14
10:21 am
scyx
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: Avidity Partners Management LP
Low
Report
Form SCHEDULE 13G/A SCYNEXIS INC Filed by: Avidity Partners Management LP
1/27
04:05 pm
scyx
Form 4 SCYNEXIS INC For: Jan 23 Filed by: Sukenick Scott
Low
Report
Form 4 SCYNEXIS INC For: Jan 23 Filed by: Sukenick Scott
1/27
04:03 pm
scyx
Form 4 SCYNEXIS INC For: Jan 23 Filed by: Macleod ivor
Low
Report
Form 4 SCYNEXIS INC For: Jan 23 Filed by: Macleod ivor
1/27
04:01 pm
scyx
Form 4 SCYNEXIS INC For: Jan 23 Filed by: Angulo Gonzalez David
Low
Report
Form 4 SCYNEXIS INC For: Jan 23 Filed by: Angulo Gonzalez David
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/8
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
18.0%
4/13 Form 8-K SCYNEXIS INC For: Apr 10 13.1%
12/10 SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants 12.2%
9/18 SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) 11.4%
11/12 SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update 9.1%
1/15 SCYNEXIS Inc (NASDAQ: SCYX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 8.1%
5/1 Form S-3 SCYNEXIS INC 7.4%
4/24 Form 8-K SCYNEXIS INC For: Apr 21 7.3%
12/20 Form SC 13G SCYNEXIS INC Filed by: ARMISTICE CAPITAL, LLC 5.9%
2/18 SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
4/13 Form 8-K SCYNEXIS INC For: Apr 10 13.1%
12/10 SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants 12.2%
9/18 SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC) 11.4%
11/12 SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update 9.1%
1/15 SCYNEXIS Inc (NASDAQ: SCYX) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 8.1%
5/1 Form S-3 SCYNEXIS INC 7.4%
4/24 Form 8-K SCYNEXIS INC For: Apr 21 7.3%
12/20 Form SC 13G SCYNEXIS INC Filed by: ARMISTICE CAPITAL, LLC 5.9%
2/18 SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.9%
TOP News Decliners
3/18
SCYNEXIS Inc (NASDAQ: SCYX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
-15.4%
7/24 SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) -13.5%
4/21 SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) -13.5%
11/14 SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States -12.1%
12/9 SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants -11.8%
3/26 SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 -11.5%
12/20 The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 32% More Shares [Yahoo! Finance News] -9.0%
12/11 Form 424B5 SCYNEXIS INC -7.8%
3/11 Form 10-K SCYNEXIS INC For: Dec 31 -7.2%
11/7 SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303) -7.0%
7/24 SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study) -13.5%
4/21 SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) -13.5%
11/14 SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States -12.1%
12/9 SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants -11.8%
3/26 SCYNEXIS to Virtually Present on the Candida Auris Treatment Landscape at the 22nd Annual Superbugs and Superdrugs Conference 2020 -11.5%
12/20 The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 32% More Shares [Yahoo! Finance News] -9.0%
12/11 Form 424B5 SCYNEXIS INC -7.8%
3/11 Form 10-K SCYNEXIS INC For: Dec 31 -7.2%
11/7 SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303) -7.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: